Tildrakizumab regulatory update

Almirall and Sun said EMA validated an MAA for tildrakizumab to treat moderate to severe plaque psoriasis. Sun has exclusive, worldwide rights to the mAb against IL-23 subunit alpha (IL23P19; IL-23A) ...